Retrospective 2,184 hospitalized patients in the USA, 638 treated with famotidine, showing lower mortality with treatment.
risk of death, 70.0% lower, OR 0.30, p < 0.001, treatment 638, control 819, adjusted per study, multivariable, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Wagner et al., 31 Oct 2021, retrospective, USA, peer-reviewed, 5 authors, study period March 2020 - March 2021.
Gastrointestinal Symptoms and Association With Respiratory Symptoms in Patients Diagnosed With SARS-CoV 2 (COVID-19)
MD Ernesto Robalino Gonzaga, MD Irene Riestra Guiance, MD Richard Henriquez, MD Mahmoud Ibrahim, MD Yuya Nway, DO Minh Ho, Jane Ha, MD, PhD Yeongkeun Kwon, BS Dohyang Kim, PhD Jinseub Hwang, PhD Jin-Won Kwon, MD, PhD Sungsoo Park
Figure 1. Panel a: Hospitalized COVID-19 patients with GI Symptoms on Admission demographic characteristics and ICU or non ICU admissions comparing with presence or no of respiratory symptoms. Panel b: Odds Ratio Estimates for ICU Admission in Patients with COVID-19 presenting with GI symptoms.